SCHEMBL20965374

SCHEMBL20965374

Cc1noc(CSc2ccccc2C(=O)N2CCN(c3ccc([N+](=O)[O-])cn3)CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.52
KMT2A Q03164 6/20 0.52
ALDH1A1 P00352 5/20 0.52
MEN1 O00255 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
LMNA P02545 4/20 0.52
PKM P14618 1/20 0.52
TSHR P16473 1/20 0.47
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
NPBWR1 P48145 1/20 0.43
MCHR1 Q99705 1/20 0.43
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 1/20 0.42
PANK3 Q9H999 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
POLB P06746 1/20 0.41
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964557 0.89 LMNA (0.67) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20964555 0.87 ALDH1A1 (0.49) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20964620 0.85 KMT2A (0.52) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20965398 0.85 LMNA (0.57) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20964687 0.80 SMN1; SMN2 (0.48) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20964937 0.77 LMNA (0.58) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20965436 0.77 L3MBTL1 (0.63) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20965289 0.73 ALDH1A1 (0.67) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20965382 0.73 ALDH1A1 (0.49) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL20964591 0.73 SMN1; SMN2 (0.80) MAPTKMT2AALDH1A1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 MAPT 1626/4885KMT2A 4728/4885ALDH1A1 141/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 MAPT 4673/4885KMT2A 3241/4885ALDH1A1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.